Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Patient Voice
Open Access

Cost of Immunosuppressive Drugs and the Patient with a Kidney Transplant

Cher Thomas
CJASN March 2019, 14 (3) 317-318; DOI: https://doi.org/10.2215/CJN.00760119
Cher Thomas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading
  • kidney transplantation
  • Costs and Cost Analysis
  • Immunosuppressive Agents
  • Patient
  • Patient Voice

I am responding to your published article “Secular Trends in the Cost of Immunosuppressants after Solid Organ Transplant in the United States” (1). I am a kidney transplant recipient and I will be celebrating my 20th kidney transplant anniversary in March 2019. I am also a registered dental hygienist. I greatly appreciate the opportunity to offer a few comments.

My opinions are on the basis of my education and professional experience as an allied health care provider, and my 21 years of living with CKD. I love science for what is has done for my dental patients and myself. My kidney disease was attributed to ANCA-positive vasculitis and I chose peritoneal dialysis as my bridge to solid organ transplantation. In 1999, I received a living related donor kidney transplant. There have been a few hiccups along the way; however, I am grateful for the independence and quality of life my transplant has given me.

In my experience, in 1999, generic medications were rarely prescribed. Even with group insurance prescription coverage, the out-of-pocket costs for some of my medications were very expensive. Taking the expense of medications into consideration, I selected to enter a double-blind immunosuppressive study for two reasons: (1) the study program provided cyclosporin free of charge, and the use of cyclosporin was mandatory; and (2) the study protocol goal was trying to offer patients a medication that would require a lower than normal dosage of cyclosporin to reduce the incidence of nephrotoxicity.

Being a patient with CKD is filled with challenges and decisions that we rarely know much about. I was fortunate to have excelled in classes such as anatomy, physiology, pharmacology, etc. I also had a network of medical colleagues that were willing to help me fill in the blanks on topics I knew nothing about. In my personal research, before my transplant, I had read about the risk of nephrotoxicity and I considered the risk versus the benefit and thought this might benefit me many years down the road. If it did not, it could provide much needed information for other patients (or myself) in the future.

After my transplant, it was in the first month that the cost of being a kidney transplant recipient was realized. My copay on just one medication was $500 and this was not an immunosuppressive medication. A hefty sum for someone who had to cut back on working to recover from surgery. Today, 20 years later, all of my medications are generic.

Although I agree with the conclusion reached by Helmuth et al.—“The decline in payments by Medicare Part D and by transplant recipients for tacrolimus, and mycophenolate between 2008 and 2013 suggests that the introduction of generic Immunosuppressants during this period has resulted in substantial cost savings to Medicare and to patients, largely reflecting the transition from brand to generic products,”—it left me with more questions.

Yes, switching patients to generic immunosuppressive agents would reduce expenses; however, I am perplexed that the qualification for graft function is only 30 days. I would like to know how many, or if any, of the patients went into rejection? If a patient ends up back on dialysis, I do not believe that would demonstrate cost savings, for it is stated, “…subsequent return to dialysis and/or retransplantation are estimated to be between $70,000 and $106,000 compared with approximately $16,000 for patients with a functioning graft.”

Also, “in all three cohorts, candidates were predominately male, white, and aged 50–64 years.” This population does not accurately reflect the racial diversity of organ transplant candidates. What would the financial estimate be with a racially diverse population?

Furthermore, the Affordable Care Act was implemented in 2011, which is about halfway through the study. Can we attribute all savings to generic medications or could it be associated with access to care?

Pharmacologic agents are required to be bioequivalent; however, they can have inert differences that may leave patients with allergic reactions or unfavorable side effects. The option/choice of receiving a generic medication (although it may provide a substantial savings to the patient in the immediate future) are now decided by insurance companies, not our health care providers. Today, I am quite frequently switched from one generic to another. I know to confirm the switch with the pharmacist to assure it is indeed my prescription; however, I fear many patients do not realize there has been a change.

My last point addresses patient participation in research. As I stated, my decision to participate in the clinical trial was influenced by financial concerns. Will patients choose to participate in clinical trials in the future? And if so, what will be their reward…their motivation? Will it become difficult to have patients agree to participate in research?

As I am someone who has put my faith in my health care providers for years, I am also inclined to do my own research and ask questions. I am very thankful for saving money on my immunosuppressive medications.

Disclosures

None.

Acknowledgments

C.T., is a real transplant recipient and a registered dental hygienist. In addition to being a patient advocate with the Renal Support Network, C.T. has authored several articles in dental and dental hygiene publications regarding the dental management of patients with CKD, ESKD, and renal transplantation. She will be celebrating her 20th renal transplant anniversary in March 2019.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • See related editorial, “Are Generic Immunosuppressive Drugs the Solution for Providing Lifelong Medication Coverage to Transplant Recipients?,” and article “Secular Trends in the Cost of Immunosuppressants after Solid Organ Transplantation in the United States,” on pages 327–329 and 421–430, respectively.

  • Copyright © 2019 by the American Society of Nephrology

References

  1. ↵
    1. Helmuth ME,
    2. Liu Q,
    3. Turenne MN,
    4. Park JM,
    5. Oguntimein M,
    6. Dutcher SK,
    7. Balkrishnan R,
    8. Sharma P,
    9. Zee J,
    10. Leichtman AB,
    11. Smith AR
    : Secular trends in the cost of immunosuppressants after solid organ transplantation in the United States. Clin J Am Soc Nephrol 14: 421–430, 2019
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 14 (3)
Clinical Journal of the American Society of Nephrology
Vol. 14, Issue 3
March 07, 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Cost of Immunosuppressive Drugs and the Patient with a Kidney Transplant
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cost of Immunosuppressive Drugs and the Patient with a Kidney Transplant
Cher Thomas
CJASN Mar 2019, 14 (3) 317-318; DOI: 10.2215/CJN.00760119

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Cost of Immunosuppressive Drugs and the Patient with a Kidney Transplant
Cher Thomas
CJASN Mar 2019, 14 (3) 317-318; DOI: 10.2215/CJN.00760119
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Changing Health Disparities in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  • Medicare Bundled Payment Policy and Anemia Care
  • COVID-19 Vaccination for Patients Undergoing Long-Term Hemodialysis
Show more Patient Voice

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Are Generic Immunosuppressive Drugs the Solution for Providing Lifelong Medication Coverage to Transplant Recipients?
  • Secular Trends in the Cost of Immunosuppressants after Solid Organ Transplantation in the United States
  • PubMed
  • Google Scholar

Keywords

  • kidney transplantation
  • Costs and Cost Analysis
  • Immunosuppressive Agents
  • patient
  • patient voice

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire